Please assess the completion status of the following clinical trial:

Trial Title: Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects with locally advanced or metastatic NSCLC (stage IIIb/IV) who have relapsed following adjuvant or first line therapy with a platinum containing regimen, and are appropriate candidates for treatment with single agent docetaxel~* Confirmed NSCLC by prior pathological analysis (tissue aspirate or biopsy)~* At least 21 days from prior chemotherapy~* At least 30 days from prior irradiation therapy~* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0 or 1~* Life expectancy of 12 weeks or more~* Adequate hematologic function \[Absolute neutrophil count (ANC) ≥ 1.5 x 10\^9/L; platelet count ≥100x10\^9/L; hemoglobin ≥8.5 g /dL maintained in the absence of red blood cell transfusions; and prothrombin time international normalized ratio ≤1.7; or prothrombin time ≤2 seconds above control)~* Adequate hepatic function (albumin ≥2.8 g/dL; total bilirubin ≤2 mg/dL \[51.3 μmol/L\]; and alanine aminotransferase and aspartate aminotransferase ≤1.5 times the upper limit of the normal range)~* Adequate renal function (serum creatinine ≤2.0 times the upper limit of the normal range or creatinine clearance ≥60 mL/min).~* At least one untreated target lesion that could be measured in one dimension, according to the Response Evaluation Criteria in Solid Tumors (RECIST)~Exclusion Criteria:~* Previous treatment with docetaxel (prior treatment with paclitaxel permitted)~* Receipt of more than one prior systemic chemotherapy regimen~* Active concomitant malignancy likely to effect any of the primary or secondary outcome measures in the current study~* Women who are pregnant, breast-feeding or planning to become pregnant during the study~* Men or women of reproductive-potential who are unwilling to use an effective method of contraception during the study and for 30 days following the last dose~* Evidence of a significant medical disorder or laboratory finding that, in the opinion of the Investigator, compromises the subject's safety during study participation~* Active Central Nervous System (CNS) metastatic disease requiring intervention~* Less than 4 weeks since major surgery~* Known human immunodeficiency virus (HIV) positivity

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Docetaxel 75 mg/m^2 (Type: ACTIVE_COMPARATOR): Subjects randomized to the docetaxel arm will be administered 75 mg/m\^2, IV, every 21 days (an approved dose and schedule)
- PR104 + 60 mg/m^2 docetaxel (Type: EXPERIMENTAL): Subjects randomized to the PR104/docetaxel arm will be administered 60 mg/m\^2 docetaxel, IV, every 21 days plus 770 mg/m\^2 PR104, IV, every 21 days and prophylactic G-CSF.

Based on this trial design, predict the completion outcome and termination type (if applicable).